{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Proportion with relapse at 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Proportion with relapse at 3 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The proportion of patients with hematologic, cytogenetic or molecular relapse of BCR/ABL-positive leukemia","groups":[{"description":"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Proportion of patients with hematologic, cytogenetic or molecular relapse of BCR/ABL-positive leukemia among those who did not die from non-relapse causes during the first year, and first 3-years after transplant.","reportingStatus":"POSTED","timeFrame":"1 and 3 years","title":"Relapse","type":"SECONDARY","unitOfMeasure":"Participants"}